286 related articles for article (PubMed ID: 15864534)
1. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
Hiukka A; Fruchart-Najib J; Leinonen E; Hilden H; Fruchart JC; Taskinen MR
Diabetologia; 2005 Jun; 48(6):1207-15. PubMed ID: 15864534
[TBL] [Abstract][Full Text] [Related]
2. Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.
Atger V; Beyne P; Frommherz K; Roullet JB; Drüeke T
Ann Biol Clin (Paris); 1989; 47(8):497-501. PubMed ID: 2690681
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
[TBL] [Abstract][Full Text] [Related]
4. [Composition and distribution of lipid and apolipoprotein in plasma lipoproteins of endogenous hypertriglyceridemia].
Zhang L; Liu B
Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):117-21. PubMed ID: 1452137
[TBL] [Abstract][Full Text] [Related]
5. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII.
Hirano T; Sakaue T; Misaki A; Murayama S; Takahashi T; Okada K; Takeuchi H; Yoshino G; Adachi M
Kidney Int; 2003 Jun; 63(6):2171-7. PubMed ID: 12753304
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto-Setälä K; Fisher EA; Chen X; Chajek-Shaul T; Hayek T; Zechner R; Walsh A; Ramakrishnan R; Ginsberg HN; Breslow JL
J Clin Invest; 1992 Nov; 90(5):1889-900. PubMed ID: 1430212
[TBL] [Abstract][Full Text] [Related]
7. Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.
Reyes-Soffer G; Sztalryd C; Horenstein RB; Holleran S; Matveyenko A; Thomas T; Nandakumar R; Ngai C; Karmally W; Ginsberg HN; Ramakrishnan R; Pollin TI
Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):63-72. PubMed ID: 30580564
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice.
Takahashi T; Hirano T; Okada K; Adachi M
Metabolism; 2003 Oct; 52(10):1354-9. PubMed ID: 14564689
[TBL] [Abstract][Full Text] [Related]
9. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
[TBL] [Abstract][Full Text] [Related]
10. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
Lee SJ; Campos H; Moye LA; Sacks FM
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):853-8. PubMed ID: 12637336
[TBL] [Abstract][Full Text] [Related]
11. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Lemieux I; Salomon H; Després JP
Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
[TBL] [Abstract][Full Text] [Related]
12. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.
Forte TM; Nichols AV; Krauss RM; Norum RA
J Clin Invest; 1984 Nov; 74(5):1601-13. PubMed ID: 6501564
[TBL] [Abstract][Full Text] [Related]
13. Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia.
Cruz-Bautista I; Mehta R; Cabiedes J; García-Ulloa C; Guillen-Pineda LE; Almeda-Valdés P; Cuevas-Ramos D; Aguilar-Salinas CA
Clin Chim Acta; 2015 Jan; 438():160-5. PubMed ID: 25172037
[TBL] [Abstract][Full Text] [Related]
14. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
[TBL] [Abstract][Full Text] [Related]
15. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
Lee SJ; Sacks FM
Am J Cardiol; 2003 Jul; 92(2):121-4. PubMed ID: 12860210
[TBL] [Abstract][Full Text] [Related]
16. Immunoturbidimetric techniques for quantifying apolipoproteins CII and CIII.
Rifai N; Silverman LM
Clin Chem; 1986 Oct; 32(10):1969-72. PubMed ID: 3093121
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein and lipid composition of plasma lipoproteins in neonates during the first month of life.
van Biervliet JP; Rosseneu M; Bury J; Caster H; Stul MS; Lamote R
Pediatr Res; 1986 Apr; 20(4):324-8. PubMed ID: 3085061
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes.
O'Looney P; Irwin D; Briscoe P; Vahouny GV
J Biol Chem; 1985 Jan; 260(1):428-32. PubMed ID: 3965456
[TBL] [Abstract][Full Text] [Related]
19. Relation of abnormal composition of lipoproteins to HbA1c levels in non-insulin dependent diabetes.
Sánchez-Cabezudo M; Ródenas S; Cuesta C
Rev Esp Fisiol; 1994 Sep; 50(3):145-51. PubMed ID: 7886271
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Hiukka A; Leinonen E; Jauhiainen M; Sundvall J; Ehnholm C; Keech AC; Taskinen MR
Diabetologia; 2007 Oct; 50(10):2067-75. PubMed ID: 17653691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
